SCHEMBL77311

SCHEMBL77311

COC(=O)c1c[nH]c(C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.59
ALDH1A1 P00352 6/20 0.49
BAZ2B Q9UIF8 1/20 0.49
BAZ2A Q9UIF9 1/20 0.49
CA1 P00915 4/20 0.48
CA2 P00918 4/20 0.48
CA12 O43570 3/20 0.48
CA7 P43166 3/20 0.48
CA9 Q16790 3/20 0.48
CA14 Q9ULX7 3/20 0.48
XDH P47989 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
KDM4E B2RXH2 3/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 2/20 0.47
NFKB1 P19838 1/20 0.47
GFER P55789 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70354 0.81 BAZ2B (0.71) ALDH1A1BAZ2BBAZ2ACA1CA2
SCHEMBL31337488 0.80 POLB (0.45) NOTUMALDH1A1BAZ2BBAZ2ACA1
SCHEMBL3000237 0.79 NOTUM (0.55) NOTUMALDH1A1CA1CA2CA12
SCHEMBL24930955 0.79 ALDH1A1 (0.46) ALDH1A1BAZ2BBAZ2ACA1CA2
SCHEMBL28966502 0.79 ALDH1A1 (0.46) ALDH1A1BAZ2BBAZ2ACA1CA2
SCHEMBL1156046 0.79 ALDH1A1 (0.46) NOTUMALDH1A1BAZ2BBAZ2ACA1
SCHEMBL12272617 0.79 ALDH1A1 (0.46) ALDH1A1BAZ2BBAZ2ACA1CA2
SCHEMBL10937890 0.79 ALDH1A1 (0.46) ALDH1A1BAZ2BBAZ2ACA1CA2
SCHEMBL22289962 0.78 NOTUM (0.53) NOTUMALDH1A1BAZ2BBAZ2ACA1
SCHEMBL409737 0.78 BAZ2B (0.57) ALDH1A1BAZ2BBAZ2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
WO-2025096637-A1 SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2025-05-08 WO disclosed
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-05-08 US disclosed
CN-119923385-A Inhibitors of RNA helicase DHX9 and uses thereof 埃克森特治疗公司 2025-05-02 CN disclosed
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2025-02-25 US disclosed
WO-2025038462-A2 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2025-02-20 WO disclosed
EP-4479138-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 EP disclosed
US-12162867-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2024-12-10 US disclosed
CN-115697991-B Piperazine cyclic ureas 维泰瑞隆有限公司 2024-11-22 CN disclosed
US-20240316047-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2024-09-26 US disclosed
US-20090192156-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2009-07-30 US disclosed
US-20090192156-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2009-07-30 US disclosed
US-5849693-A Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-12-15 US disclosed
US-5773411-A CARDIOVASCULAR DISORDERS AND BRAIN DISORDERS AND COAGULANTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-30 US disclosed
US-5691329-A Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-11-25 US disclosed
US-5563158-A CARDIOVASCULAR DISORDERS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-10-08 US disclosed
EP-0672059-A1 CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-09-20 EP disclosed
WO-1995018111-A1 COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-07-06 WO disclosed
WO-1994011398-A1 CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-05-26 WO disclosed
EP-0300688-A1 Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them FISONS plc (GB) 1989-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316047-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX29, DHX9, DDX39B NOTUM 4124/4885ALDH1A1 1705/4885BAZ2B 777/4885
US-20090192156-A1 PHTHALAZINONE DERIVATIVES CBR1, CBR3, SDHA NOTUM 4480/4885ALDH1A1 546/4885BAZ2B 515/4885
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B NOTUM 4124/4885ALDH1A1 1705/4885BAZ2B 777/4885
US-12162867-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B NOTUM 3887/4885ALDH1A1 1333/4885BAZ2B 732/4885
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B NOTUM 3762/4885ALDH1A1 1127/4885BAZ2B 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.